Mahalo no kou kipa ʻana iā Nature.com. ʻO ka polokalamu kele pūnaewele āu e hoʻohana nei he kākoʻo CSS kaupalena. No ka ʻike maikaʻi loa, paipai mākou iā ʻoe e hoʻohana i kahi polokalamu kele pūnaewele hou (a i ʻole e hoʻopau i ke ʻano Compatibility Mode ma Internet Explorer). I kēia manawa, e hōʻoia i ke kākoʻo mau ʻana, e hāʻawi mākou i ka pūnaewele me ka ʻole o nā ʻano a me JavaScript.
Hoʻohana nui ʻia nā peptides a me nā protein no ka mālama ʻana i nā maʻi like ʻole, akā maʻamau e hoʻopili ʻia lākou a pōkole ka hopena. Hiki ke hoʻopau ʻia kēia mau hemahema o nā hale maoli me ke kōkua o ka ʻenekinia molekula, akā he hana paʻakikī kēia. ʻO nā ʻenehana ʻenekinia molekula, i hoʻohana mua ʻia i ka insulin a i kēia manawa ua hoʻohana maikaʻi ʻia i kekahi mau biopharmaceuticals, koi i ka derivatization o nā peptides a me nā protein mai nā waikawa momona. Hiki i nā ʻano kikoʻī a me kahi o nā ʻakika momona i hoʻopili ʻia ke hāʻawi i nā ʻano hana elongation like ʻole. Eia hou, hiki i kēia ʻenehana ke hāʻawi i ka hapalua o ke ola ma hope o ka hoʻohana waha ʻana i nā lāʻau peptide, hiki ke hoʻololi i ka hāʻawi ʻana i nā peptides, a loaʻa paha ka mana no ka huli ʻana i nā kiko. Me ka palekana maoli o nā ʻakika momona a me nā waiwai kemika i wehewehe maikaʻi ʻia, hāʻawi kēia ʻenehana i kahi ala kūpono i ka peptide a me ka ʻike ʻana i ka lāʻau lapaʻau.
Uena na kumukuai a pau. E hoʻohui ʻia ka VAT ma hope i ka wā kūʻai. E hana ʻia nā helu ʻauhau ma ka hale kūʻai.
Muttenthaler, M., King, GF, Adams, DJ & Alewood, PF Trends in peptide drug discovery. Muttenthaler, M., King, GF, Adams, DJ & Alewood, PF Trends in peptide drug discovery.Muttenthaler, M., King, GF, Adams, DJ a me Alevud, PF Trends i ka ʻike lāʻau peptide. Muttenthaler, M., King, GF, Adams, DJ & Alewood, PF 多肽药物发现的趋势。 Muttenthaler, M., King, GF, Adams, DJ & Alewood, PFMuttenthaler, M., King, GF, Adams, DJ a me Alevud, PF Trends i ka ʻike lāʻau peptide.Lahui Ka wehe ana o ke kahunapule laau. 20, 309–325 (2021). Ke nānā nei kēia loiloi i nā ʻano o kēia manawa a me ka wā e hiki mai ana o ka ʻike ʻana i ka lāʻau peptide.
Müller, TD, Blüher, M., Tschöp, MH & DiMarchi, RD ʻO ka loaʻa ʻana o ka lāʻau lapaʻau anti-obesity: holomua a me nā pilikia. Müller, TD, Blüher, M., Tschöp, MH & DiMarchi, RD ʻO ka loaʻa ʻana o ka lāʻau lapaʻau anti-obesity: holomua a me nā pilikia.Müller, TD, Blucher, M., Chop, MH a me DiMarchi, RD Anti-obesity ʻike lāʻau lapaʻau: holomua a me nā pilikia. Müller, TD, Blüher, M., Tschöp, MH & DiMarchi, RD 抗肥胖药物发现：进展和挑战。 Müller, TD, Blüher, M., Tschöp, MH & DiMarchi, RDMüller, TD, Blucher, M., Chop, MH a me DiMarchi, RD Anti-obesity ʻike lāʻau lapaʻau: holomua a me nā pilikia.Lahui Ka wehe ana o ke kahunapule laau. 21, 201–223 (2022). Hāʻawi kēia loiloi i kahi ʻike i nā pilikia o ka momona, ʻoi aku ka manaʻo hou e pili ana i nā peptides.
ʻO Strohl, WR Fusion proteins e hoʻolōʻihi i ka hapalua o ke ola o ka biologics e like me ka hoʻolālā maikaʻi loa no ka biologics. Biopharmaceutics 29, 215–239 ​​(2015).
Evans, M. et al. ʻO ka mālama ʻana a me ka hoʻomau ʻana o nā lāʻau antidiabetic a me ka hui pū ʻana me nā hopena lapaʻau a me ka hoʻokele waiwai i nā maʻi me ka maʻi diabetes type 2: kahi loiloi ʻōnaehana o ka palapala. ʻobesity diabetic. metabolism. 24, 377–390 (2022).
Polonsky, WH, Fisher, L., Hessler, D., Bruhn, D. & Best, JH Nā manaʻo maʻi i nā lāʻau lapaʻau hoʻokahi pule no ka maʻi diabetes. Polonsky, WH, Fisher, L., Hessler, D., Bruhn, D. & Best, JH Nā manaʻo maʻi i nā lāʻau lapaʻau hoʻokahi pule no ka maʻi diabetes.Polonsky WH, Fisher L., Hessler D., Brune D., a me ka Best JH He manaʻo o ka mea maʻi i nā lāʻau maʻi diabetes i hoʻokahi pule. Polonsky, WH, Fisher, L., Hessler, D., Bruhn, D. & Best, JH 患者对每周一次的糖尿病药物的看法。 Polonsky, WH, Fisher, L., Hessler, D., Bruhn, D. & Best, JHPolonsky WH, Fisher L., Hessler D., Brune D., a me ka ʻike maʻi maikaʻi loa ʻo JH o nā lāʻau maʻi diabetes i hoʻokahi pule.ʻobesity diabetic. metabolism. 13, 144–149 (2011).
Hashimoto, M., Takada, K., Kiso, Y. & Muranishi, S. Synthesis of palmitoyl derivatives of insulin and their biological activities. Hashimoto, M., Takada, K., Kiso, Y. & Muranishi, S. Synthesis of palmitoyl derivatives of insulin and their biological activities.Hashimoto M., Takada K., Kiso Y. a me Muranishi S. Synthesis of palmitoyl derivatives of insulin and their biological activity. Hashimoto, M., Takada, K., Kiso, Y. & Muranishi, S. 胰岛素棕榈酰衍生物的合成及其生物活性。 Hashimoto, M., Takada, K., Kiso, Y. & Muranishi, S. Synthesis and biological activity of insulin palmitoyl derivatives.Hashimoto M., Takada K., Kiso Y. a me Muranishi S. Synthesis a me ka hana olaola o ka insulin palmitoyl derivatives.waihona lāʻau 6, 171–176 (1989).
Kurtzhals, P. et al. ʻO ka Albumin e hoʻopaʻa ana i ka insulin acid-acylate: ke ʻano o ka pilina ligand-protein a me ka pilina ma waena o ka pilina paʻa a me ka manawa hana insulin i vivo. biochem. J. 312, 725–731 (1995). ʻO kēia hana ka mea mua i hōʻike i ka piʻi ʻana o ka hapalua o ke ola ma muli o ka hoʻopaʻa ʻana o albumin i nā peptides i loaʻa mai nā momona momona.
Mejuch, T. & Waldmann, H. Synthesis of lipidated proteins. Mejuch, T. & Waldmann, H. Synthesis of lipidated proteins.Meyukh, T. a me Waldmann, H. Synthesis of lipidated proteins. Mejuch, T. & Waldmann, H. 脂化蛋白质的合成。 Mejuch,T. & Waldmann,H.Meyukh, T. a me Waldmann, H. Synthesis of lipidated proteins.Bioconjugate. Kemika. 27, 1771–1783 (2016).
Chen, B., Sun, Y., Niu, J., Jarugumilli, GK & Wu, X. Protein lipidation i ka hōʻailona cell a me nā maʻi: hana, hoʻoponopono, a me nā manawa kūpono. Chen, B., Sun, Y., Niu, J., Jarugumilli, GK & Wu, X. Protein lipidation i ka hōʻailona cell a me nā maʻi: hana, hoʻoponopono, a me nā manawa kūpono.Chen B., Sun Y., Niu J., Jarugumilli GK a me Wu X. Protein lipidation i ka hōʻailona cell a me ka maʻi: hana, hoʻoponopono, a me ka hiki ke hoʻoponopono. Chen, B., Sun, Y., Niu, J., Jarugumilli, GK & Wu, X. Chen, B., Sun, Y., Niu, J., Jarugumilli, GK & Wu, X. Protein脂化 i ka hōʻailona cell a me ka maʻi: hana, hoʻoponopono a me nā manawa kūpono.Chen B., Sun Y., Niu J., Jarugumilli GK a me Wu X. Protein lipidation i ka hōʻailona cell a me ka maʻi: hana, hoʻoponopono, a me ka hiki ke hoʻoponopono.cytochemistry. biology 25, 817–831 (2018).
Richter, WF, Bhansali, SG & Morris, ME Mechanistic determinants o ka biotherapeutics absorption ma hope o ka hoʻokele SC. Richter, WF, Bhansali, SG & Morris, ME Mechanistic determinants o ka biotherapeutics absorption ma hope o ka hoʻokele SC.Richter, VF, Bhansali, SG a me Morris, ME Mechanisms e hoʻoholo i ka absorption o nā mea biotherapeutic ma hope o ka hoʻokele subcutaneous. Richter, WF, Bhansali, SG & Morris, ME SC 给药后生物治疗药物吸收的机制决定因素。 Richter, WF, Bhansali, SG & Morris, ME SC Richter, WF, Bhansali, SG & Morris, ME SC Механистические детерминанты абсорбции биотерапевтических препаратов после введения. Richter, WF, Bhansali, SG & Morris, ME SC Nā mea hoʻoholo mīkini o ka absorption o nā lāʻau biotherapeutic ma hope o ka lawelawe ʻana.AAPS J. 14, 559–570 (2012).
Gradel, AKJ et al. ʻO nā mea e pili ana i ka absorption insulin subcutaneous: nā hopena no ka loli. J. Diabetes Res. 2018, 1205121 (2018).
Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L. Hoʻoholo ka diffusion a me ka polymerization i ka absorption insulin mai ke kino subcutaneous i nā maʻi diabetic. Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L. Hoʻoholo ka diffusion a me ka polymerization i ka absorption insulin mai ke kino subcutaneous i nā maʻi diabetic. Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L. диабетом. Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L. Hoʻoholo ka diffusion a me ka polymerization i ka absorption insulin mai ke kino subcutaneous i nā maʻi diabetic. Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L. 扩散和聚合决定了糖尿病患者皮下组织对胰岐的。 Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L. Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L. диабетом. Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L. Hoʻoholo ka diffusion a me ka hui ʻana i ka absorption insulin subcutaneous i nā maʻi maʻi maʻi.ka nānā ʻana. J. Klin. hale hoʻokolohua. hoʻokomo kālā. 45, 685–690 (1985).
Mosekilde, E., Jensen, KS, Binder, C., Pramming, S. & Thorsteinsson, B. Ke hoʻohālike nei i nā kinetics absorption o subcutaneous injected soluble insulin. Mosekilde, E., Jensen, KS, Binder, C., Pramming, S. & Thorsteinsson, B. Ke hoʻohālike nei i nā kinetics absorption o subcutaneous injected soluble insulin.Mosekilde E, Jensen KS, Binder S, Pramming S, a me Thorsteinsson B. Hoʻohālike i nā kinetics absorption o ka insulin soluble subcutaneous. Mosekilde, E., Jensen, KS, Binder, C., Pramming, S. & Thorsteinsson, B. 模拟皮下注射可溶性胰岛素的吸收动力学。 Mosekilde, E., Jensen, KS, Binder, C., Pramming, S. & Thorsteinsson, B.Mosekilde E, Jensen KS, Binder S, Pramming S, a me Thorsteinsson B. Hoʻohālike i nā kinetics absorption o ka insulin soluble i lawelawe ʻia ma lalo o ke kino.J. Pharmacokinetics. biopharmacy. 17, 67–87 (1989).
Kuna, M., Mahdi, F., Chade, AR & Bidwell, GL III Molecular size modulates pharmacokinetics, biodistribution, and renal deposition of the drug delivery biopolymer elastin-like polypeptide. Kuna, M., Mahdi, F., Chade, AR & Bidwell, GL III Molecular size modulates pharmacokinetics, biodistribution, and renal deposition of the drug delivery biopolymer elastin-like polypeptide. Kuna, M., Mahdi, F., Chade, AR & Bidwell, GL III. эластиноподобного полипептида для доставки лекарственного средства. Kuna, M., Mahdi, F., Chade, AR & Bidwell, GL III Molecular size modulates pharmacokinetics, biodistribution, and renal deposition of biopolymeric elastin-like polypeptide for drug delivery. Kuna, M., Mahdi, F., Chade, AR & Bidwell, GL III分子大小调节药物递送生物聚合物弹性蛋白样多肽的药代动力学、生物和物分大。 Kuna, M., Mahdi, F., Chade, AR & Bidwell, GL III MoleculeKuna, M., Mahdi, F., Chad, AR a me Bidwell, GL III. Pharmacokinetics, biodistribution a me renal deposition o biopolymeric elastin-like polypeptides modulating i ka nui o ka mole.Hōʻike ʻepekema 8, 7923 (2018).
Harris, JM, Martin, NE & Modi, M. Pegylation: kahi hana hou no ka hoʻololi ʻana i nā pharmacokinetics. Harris, JM, Martin, NE & Modi, M. Pegylation: kahi hana hou no ka hoʻololi ʻana i nā pharmacokinetics. Harris, JM, Martin, NE & Modi, M. Пегилирование: новый процесс модификации фармакокинетики. Harris, JM, Martin, NE & Modi, M. Pegylation: kahi hana hou no ka hoʻololi ʻana i nā pharmacokinetics. Harris, JM, Martin, NE & Modi, M. 聚乙二醇化：一种改变药代动力学的新方法。 Harris, JM, Martin, NE & Modi, M. 聚乙二感化: kahi ala hou e hoʻololi ai i ka lāʻau lapaʻau. Harris, JM, Martin, NE & Modi, M. Пегилирование: новый подход к изменению фармакокинетики. Harris, JM, Martin, NE & Modi, M. Pegylation: kahi ala hou e hoʻololi ai i nā pharmacokinetics.lāʻau lapaʻau. Pharmacokinetics. 40, 539–551 (2001).
Elmerer, M. et al. ʻO ke ana o ka albumin interstitial i loko o ka ʻiʻo iwi iwi a me ka ʻiʻo adipose e ka microperfusion wehe. ʻAe. J. Pilikino. endocrine. metabolism. 278, E352-E356 (2000).
Nelson, J. et al. ʻO ka hapalua o ke ola o ka albumin i loko o ke kanaka e pono ai i kahi C-terminus paʻa. kamaʻilio. biology. 3, 181 (2020).
Chowdhury, K. et al. ʻO ka mea hoʻokipa Fc (FcRn) no IgG pili me ka paʻakikī histocompatibility nui e hoʻopaʻa i ka albumin a hoʻolōʻihi i kona ola. J. Exp. lāʻau lapaʻau. 197, 315–322 (2003).
Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, ES Exocytosis o IgG e like me ka mediated e ka mea loaʻa, FcRn: he loiloi ma ka pae hoʻokahi-molele. Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, ES Exocytosis o IgG e like me ka mediated e ka mea loaʻa, FcRn: he loiloi ma ka pae hoʻokahi-molele. Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, ES Экзоцитоз IgG, опосредованный рецептором FcRn: анализ на уровне одной молекулы. Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, ES FcRn receptor-mediated IgG exocytosis: hoʻokahi-molele analysis. Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, ES 受体介导的IgG 胞吐作用，FcRn：单分子水平的分析。 Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, ES Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, Экзоцитоз IgG, опосредованный рецептором ES, FcRn: анализ на уровне одной молеклы. Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, ES receptor-mediated IgG exocytosis, FcRn: hoʻokahi mole-level analysis.kaʻina hana. National Academy of Science. ka ʻepekema. US 101, 11076 (2004).
ʻO ia, XM & Carter, DC Atomic structure a me ke kemika o ke kanaka serum albumin. ʻO ia, XM & Carter, DC Atomic structure a me ke kemika o ke kanaka serum albumin.On, XM and Carter, DC Atomic structure and chemistry of human serum albumin. He, XM & Carter, DC 人血清白蛋白的原子结构和化学。 ʻO ia, XM & Carter, DC.On, XM and Carter, DC Atomic structure and chemistry of human serum albumin.Nature 358, 209–215 (1992).
ʻO Curry, S., Mandelkow, H., Brick, P. & Franks, N. ʻO ke ʻano kristal o ka albumin serum kanaka i hoʻopili ʻia me ka waikawa momona e hōʻike ana i kahi mahele like ʻole o nā wahi paʻa. ʻO Curry, S., Mandelkow, H., Brick, P. & Franks, N. ʻO ke ʻano kristal o ka albumin serum kanaka i hoʻopili ʻia me ka waikawa momona e hōʻike ana i kahi mahele like ʻole o nā wahi paʻa.ʻO Curry S., Mandelkow H., Brick P. a me Franks N. ʻO ke ʻano aniani o ka albumin serum kanaka i loko o ka paʻakikī me kahi momona momona e hōʻike ana i ka mahele like ʻole o nā wahi paʻa. Curry, S., Mandelkow, H., Brick, P. & Franks, N. ʻO Curry, S., Mandelkow, H., Brick, P. & Franks, N. ʻO ke ʻano aniani o ka paʻakai keʻokeʻo keʻokeʻo kanaka me nā ʻakika momona e hōʻike ana i ka mahele asymmetric o nā wahi paʻa.ʻO Curry S., Mandelkow H., Brick P. a me Franks N. ʻO ke ʻano aniani o ka albumin serum kanaka i loko o ka paʻakikī me nā ʻakika momona e hōʻike ana i kahi mahele asymmetric o nā wahi paʻa.Nat. hale kūkulu. biology 5, 827–835 (1998). Hōʻike kēia pepa i ke kumu hoʻonohonoho o ka hoʻopaʻa ʻana i nā ʻakika momona i ka albumin serum.
Irby, D., Du, C. & Li, F. Lipid-lāʻau conjugate no ka hoʻonui ʻana i ka lawe ʻana i ka lāʻau. Irby, D., Du, C. & Li, F. Lipid-lāʻau conjugate no ka hoʻonui ʻana i ka lawe ʻana i ka lāʻau.Irby, D., Du, K. a me Li, F. Lipid-lāʻau conjugates no ka hoʻonuiʻana i ka lāʻau. Irby, D., Du, C. & Li, F. Lipid-lāʻau conjugate no ka hoʻonui ʻana i ka lawe lāʻau. Irby, D., Du, C. & Li, F. Lipid-lāʻau conjugate no ka hoʻonui ʻana i ka lawe lāʻau.Irby, D., Du, K. a me Li, F. Lipid-lāʻau conjugate no ka hoʻonuiʻana i ka lāʻau.Biochemistry 14, 1325–1338 (2017).
ʻO Torchilin VP Ke holomua nei i ke kahua o nā liposomes ma ke ʻano he lawe lāʻau. Lahui Ka wehe ana o ke kahunapule laau. 4, 145–160 (2005).
Bhat, M., Jatyan, R., Mittal, A., Mahato, RI & Chitkara, D. Nā manawa kūpono a me nā pilikia o ka momona momona conjugated therapeutics. Bhat, M., Jatyan, R., Mittal, A., Mahato, RI & Chitkara, D. Nā manawa kūpono a me nā pilikia o ka momona momona conjugated therapeutics.Bhat, M., Jatyan, R., Mittal, A., Mahato, RI a me Chitkara, D. Nā manawa kūpono a me nā pilikia o ka momona momona conjugated therapeutics. Bhat, M., Jatyan, R., Mittal, A., Mahato, RI & Chitkara, D. 脂肪酸共轭疗法的机遇和挑战。 Bhat, M., Jatyan, R., Mittal, A., Mahato, RI & Chitkara, D. Fatty acid 共续电影的机遇和challenge.Bhat M., Jatyan R., Mittal A., Mahato RI a me Chitkara D. Nā mea hiki a me nā pilikia o ka hoʻomaʻamaʻa ʻana i ka momona momona.Kemika. physics Lipid 236, 105053 (2021).
Smith, R. & Tanford, C. Hydrophobicity o ke kaulahao loloa n-alkyl carboxylic acids, e like me ke ana ana ma ko lakou mahele ana ma waena o ka heptane a me ka wai. Smith, R. & Tanford, C. Hydrophobicity o ke kaulahao loloa n-alkyl carboxylic acids, e like me ke ana ana ma ko lakou mahele ana ma waena o ka heptane a me ka wai.Smith, R. a me Tanford, K. Hydrophobicity o nā kaulahao lōʻihi n-alkylcarboxylic acids i ana ʻia e ko lākou māhele ʻana ma waena o ka heptane a me ka wai. Smith, R. & Tanford, C. 长链正烷基羧酸的疏水性，通过它们在庚烷和水溶液之间的分布来测量。 Smith, R. & Tanford, C. ʻO ka hydrophobicity o 长链正alkylcarboxylate, i ana ʻia e ko lākou mahele ʻana ma waena o ka hydrogen peroxide a me ka wai wai.Smith, R. a me Tanford, K. Hydrophobicity o nā kaulahao lōʻihi n-alkylcarboxylic acids i ana ʻia e ko lākou māhele ʻana ma waena o ka heptane a me ka wai.kaʻina hana. National Academy of Sciences. ʻepekema US 70, 289 (1973).
Liu, J. et al. ʻIke ʻia i hoʻokahi pule o ka analog semaglutide o glucagon-like peptide-1 (GLP-1). J. Laau lapaau. Kemika. 58, 7370–7380 (2015). Hōʻike kēia hana no ka manawa mua i ka hiki ke hoʻohana i hoʻokahi manawa i ka pule i nā ʻano derivatization fatty acid.
Østergaard, S. et al. Ka hopena o ke kanaka PYY3-36 dibasic fatty acid acylation ma ka hana liʻiliʻi puaʻa Y2 a me ka hapalua o ke ola. ka ʻepekema. Hōʻike 11, 21179 (2021). Hōʻike kēia ʻatikala i ke koʻikoʻi o ke kūlana fatty acid, ka loulou a me ka paʻa o ka iwi kuamoʻo i ka hoʻomohala ʻana i nā analogs PYY lōʻihi hapalua-ola.
Ensenat-Vaser, R. et al. Ua nānā pono ʻia ke komo ʻana o nā peptides myristoylated ma waena o ka membrane cell me ka hoʻohana ʻana i ka microscopy fluorescence confocal. IUBMB Life 54, 33–36 (2002).
Nelson, AR, Borland, L., Allbritton, NL & Sims, CE ʻO ka lawe ʻana i nā peptides e pili ana i Myristoyl i loko o nā cell ola. Nelson, AR, Borland, L., Allbritton, NL & Sims, CE ʻO ka lawe ʻana i nā peptides e pili ana i Myristoyl i loko o nā cell ola.Nelson AR, Borland L, Allbritton NL. a me Sims SE Peptide ka lawe ʻana i loko o nā keena ola e pili ana i ka myristoyl. Nelson, AR, Borland, L., Allbritton, NL & Sims, CE 基于肉豆蔻酰的肽转运到活细胞中。 Nelson, AR, Borland, L., Allbritton, NL & Sims, CE.Nelson, AR, Borland, L., Albritton, NL. a me Sims, KE Ka lawe ʻana i nā peptides i hoʻokumu ʻia myristoyl i loko o nā cell ola.Biochemistry 46, 14771–14781 (2007).
Kabanov, AV, Levashov, AV & Alakhov, VY Lipid hoʻololi o nā protein a me kā lākou lawe membrane. Kabanov, AV, Levashov, AV & Alakhov, VY Lipid hoʻololi o nā protein a me kā lākou lawe membrane.Kabanov AV, Levashov AV, Alakhov V.Yu. ʻO ka hoʻololi ʻana o ka lipid o nā protein a me kā lākou lawe membrane. Kabanov, AV, Levashov, AV & Alakhov, VY 蛋白质的脂质修饰及其膜转运。 Kabanov, AV, Levashov, AV & Alakhov, VYKabanov AV, Levashov AV, Alakhov, Lipid hoʻololi o nā protein VY a me kā lākou lawe membrane.ʻenekinia protein. Dek. Searl. 3, 39–42 (1989).
ʻO Gao, X., Mazière, AD, Beard, R., Klumperman, J. & Hannoush, RN Fatty acylation e hoʻonui i ka internalization cellular a me ka hāʻawi cytosolic o kahi peptide cystine-knot. ʻO Gao, X., Mazière, AD, Beard, R., Klumperman, J. & Hannoush, RN Fatty acylation e hoʻonui i ka internalization cellular a me ka hāʻawi cytosolic o kahi peptide cystine-knot.Gao, X., Mazier, AD, Byrd, R., Klumperman, J. a me Hannoosh, RN Fatty acid acylation e hoʻonui i ka internalization cellular a me ka hāʻawi cytosolic o kahi peptide me kahi loop cystine. Gao, X., Mazière, AD, Beard, R., Klumperman, J. & Hannoush, RN 脂肪酰化增强了胱氨酸结肽的细胞内化和胞质分布。 Gao, X., Mazière, AD, Beard, R., Klumperman, J. & Hannoush, RN.Gao, X., Mazier, AD, Byrd, R., Klumperman, J. a me Hannoosh, RN Fatty acylation e hoʻonui i ka internalization cellular a me ka hāʻawi cytoplasmic o nā peptides cystine.iScience 24, 103220 (2021).
Baker, EM et al. ʻO ka hoʻololi ʻana i ka hapalua o ke ola o ka peptide YY3-36 no ka internalization i hoʻopaʻa ʻia i ka mea hoʻokipa. Moore. lāʻau lapaʻau. 16, 3665–3677 (2019).
Mäde, V., Bellmann-Sickert, K., Kaiser, A., Meiler, J. & Beck-Sickinger, AG ʻO ke kūlana a me ka lōʻihi o nā momona momona e hoʻopili ikaika i ke ʻano koho koho o nā analogues polypeptide pancreatic kanaka. Mäde, V., Bellmann-Sickert, K., Kaiser, A., Meiler, J. & Beck-Sickinger, AG ʻO ke kūlana a me ka lōʻihi o nā momona momona e hoʻopili ikaika i ke ʻano koho koho o nā analogues polypeptide pancreatic kanaka.Hana ʻia, W., Bellmann-Sickert, K., Kaiser, A., Mailer, J. a me Beck-Sickinger, AG ʻO ke kūlana a me ka lōʻihi o nā momona momona e hoʻoikaika ikaika i ke ʻano koho o nā pancreatic polypeptide analog receptors. Mäde, V., Bellmann-Sickert, K., Kaiser, A., Meil​​er, J. & Beck-Sickinger, AG脂肪酸的位置和长度强烈影响人胰腺多肽类似物的受体选择性模式。 Mäde, V., Bellmann-Sickert, K., Kaiser, A., Meil​​er, J. & Beck-Sickinger, AGHana ʻia, W., Bellmann-Sickert, K., Kaiser, A., Mailer, J. a me Beck-Sickinger, AG ʻO ke kūlana a me ka lōʻihi o nā momona momona e hoʻoikaika nui i ke ʻano koho o nā pancreatic analog polypeptide receptors.HimMedChem 9, 2463–2474 (2014).
Aleksopoulou, F. et al. ʻO ka lipid metabolite PrRP31 kahi hana lōʻihi GPR10 a me NPFF2 receptor agonist me nā hopena pohō kaumaha. ka ʻepekema. Hōʻike 12, 1696 (2022). Hōʻike kēia haʻawina hoʻonaʻauao i ka ʻokoʻa ma waena o nā kaulahao ʻaoʻao mono a me ka diacid.
Poulsen, K. et al. Hoʻomohala kūpono o nā agonists paʻa o ka Y2 receptor peptide PYY3-36. lāʻau lapaʻau. pahu waihona. 38, 1369–1385 (2021).
Conde-Frieboes, K. et al. ʻO ka ʻike a me ke ʻano o ka in vitro a in vivo analogues o ka hana lōʻihi a me ke koho melanocortin 4 receptor (MC4-R) alpha-melanocyte-stimulating hormone (alpha-MSH). J. Laau lapaau. Kemika. 55, 1969–1977 (2012).
Ramirez-Andersen, HS et al. ʻO nā analogues ulu ulu kanaka lōʻihi i hoʻopaʻa ʻia i ka albumin non-covalent. Bioconjugate. Kemika. 29, 3129–3143 (2018).
Madsen, K. et al. Ka pilina hana-hana a me ka lōʻihi o ka glucagon-like peptide-1 derivatives: ke koʻikoʻi o ka lōʻihi o ka momona momona, polarity, a me ka nui. J. Laau lapaau. Kemika. 50, 6126–6132 (2007).
Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. Nā hua hua GLP-1 pālua-acylate. Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. Nā hua hua GLP-1 pālua-acylate. Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. Дважды ацилированные производные GLP-1. Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. Nā huaʻai acylated pālua o GLP-1. Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. 双酰化GLP-1 衍生物。 Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. 双酰化GLP-1 衍生物。 Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. Диацилированные производные GLP-1. Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. Diacylated derivatives o GLP-1.US Patent WO2012/140117 (2012).
Opio, P.-Yu. E kali. ʻO nā analogs GLP-1 ikaika a lōʻihi i hoʻolālā ʻia no ka lawe transdermal e pili ana i ka microstructure. kaʻina hana. National Academy of Science. ka ʻepekema. US 113, 4140–4145 (2016).
Royalty, JE, Konradsen, G., Eskerod, O., Wulff, BS & Hansen, BS Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese nā kumuhana. Royalty, JE, Konradsen, G., Eskerod, O., Wulff, BS & Hansen, BS Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese nā kumuhana.Royalty, JE, Konradsen, G., Eskerod, O., Wolf, BS a me Hansen, BS Safety, tolerability, pharmacokinetics, and pharmacodynamics study of single and multiple doses of long-acting α-MSG analog in health overweight and obese subjects.版税, JE, Konradsen, G., Eskerod, O., Wulff, BS & Hansen, BS 单剂量和多剂量长效α-MSH类似物在健康超重和肥胖患者中的安全性、耐受性、药代动力学和药效学和药效学破。版税, JE, Konradsen, G., Eskerod, O., Wulff, BS & Hansen, BS Hoʻokahi kaʻina a me ka nui ka hopena lōʻihi α-MSH全健康超重和肥胖可以中可以可以而受性、药代报学学和药效学研究科目。Royalty, JE, Konradsen, G., Eskerod, O., Wolf, BS a me Hansen, BS Safety, tolerability, pharmacokinetics o hoʻokahi a me ka nui o nā analogues alpha-MSG hana lōʻihi i nā kumuhana olakino a me ka momona. Kinetics a me ka pharmacodynamics.J. Clin. Pharmacodynamics. 54, 394–404 (2014).
Lau, J., F., Kruse, T., Linderoth, L. & Thøgersen, H. Novel glucagon analogues. Lau, J., F., Kruse, T., Linderoth, L. & Thøgersen, H. Novel glucagon analogues.Lau, J., F., Kruse, T., Linderoth, L. a me Togersen, H. New glucagon analogues. Lau, J., F., Kruse, T., Linderoth, L. & Thøgersen, H. 新型胰高血糖素类似物。 Lau, J., F., Kruse, T., Linderoth, L. & Thøgersen, H.Lau, J., F., Cruz, T., Linderoth, L. a me Togersen, H. New glucagon analogues.US Patent WO2011/117416 A1 (2011).
Ward, BP et al. Hoʻopaʻa ka lipidation o nā peptides i nā hale e hoʻomaikaʻi i ka hana biological. Moore. metabolism. 2, 468–479 (2013). Hōʻike kēia hana i ke kuleana o nā kaulahao ʻaoʻao momona momona i ka hoʻoholo ʻana i ke kūpaʻa o ke kūkulu ʻana a me ka hoʻopaʻa ʻana o nā mea hoʻopaʻa lāʻau peptide.
Koskun T. et al. LY3298176, kahi moʻolelo ʻelua GIP a me GLP-1 receptor agonist no ka mālama ʻana i ka maʻi maʻi type 2: mai ka ʻike ʻana i ka hōʻoia o ka manaʻo. Moore. metabolism. 18, 3-14 (2018). Hōʻike kēia pepa i ka hoʻolālā ʻana o ka mea mua i loaʻa i ka momona momona GLP-1/GIP co-agonist no hoʻokahi pule pule ma ke keʻena.
Kjeldsen, TB et al. ʻO ka ʻenekinia molekula o ka insulin icodec, ka analog insulin acylated mua i hoʻokahi pule i ke kanaka. J. Laau lapaau. Kemika. 64, 8942–8950 (2021). Hōʻike kēia pepa i ka hoʻomohala mua ʻana o ka ʻakika momona i loaʻa i ka insulin no hoʻokahi pule pule.
van Witteloostein, SB et al. ʻO Neoglycolipids no nā peptides lōʻihi: hoʻohui ponoʻī iā ia iho o ka glucagon-like peptide 1 me nā waiwai paʻa albumin a kiʻekiʻe i ka vivo potency. Moore. lāʻau lapaʻau. 14, 193–205 (2017).
Zorzi, A., Middendorp, SJ, Wilbs, J., Deyle, K. & Heinis, C. Acylated heptapeptide e hoʻopaʻa i ka albumin me ka pilina kiʻekiʻe a me ka hoʻohana ʻana e like me ka hoʻolako ʻana i nā peptides lōʻihi. Zorzi, A., Middendorp, SJ, Wilbs, J., Deyle, K. & Heinis, C. Acylated heptapeptide e hoʻopaʻa i ka albumin me ka pilina kiʻekiʻe a me ka hoʻohana ʻana e like me ka hoʻolako ʻana i nā peptides lōʻihi.ʻO Zorzi, A., Middendorp, SJ, Wilbs, J., Dale, K. a me Haynes, S. Acylate heptapeptide e hoʻopaʻa i ka albumin me ka pilina kiʻekiʻe, aʻo kona hoʻohanaʻana ma keʻano he lepili e hāʻawi i kahi peptide lōʻihi. Zorzi, A., Middendorp, SJ, Wilbs, J., Deyle, K. & Heinis, C. Zorzi, A., Middendorp, SJ, Wilbs, J., Deyle, K. & Heinis, C.Zorzi, A., Middendorp, SJ, Wilbs, J., Dale, K. a me Haynes, S. Acylated heptapeptides hoʻopaʻa i ka albumin me ka pilina kiʻekiʻe a lilo i mau lepili no ka lawe ʻana i ka peptide lōʻihi.Nat. kamaʻilio 8, 16092 (2017).